Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer
Posterior reversible encephalopathy syndrome (PRES) is an increasingly recognizable neuro-clinical syndrome. Clinical and neurological manifestations of PRES include hypertension, headache, encephalopathy, seizures, and symmetrical white matter changes on brain MRI. Most common precipitants of PRES...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Greater Baltimore Medical Center
2018-05-01
|
| Series: | Journal of Community Hospital Internal Medicine Perspectives |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20009666.2018.1478563 |
| _version_ | 1797967148656623616 |
|---|---|
| author | Mohsin Hamid Ali Ghani Ida Micaily Usman Sarwar Bilal Lashari Faizan Malik |
| author_facet | Mohsin Hamid Ali Ghani Ida Micaily Usman Sarwar Bilal Lashari Faizan Malik |
| author_sort | Mohsin Hamid |
| collection | DOAJ |
| description | Posterior reversible encephalopathy syndrome (PRES) is an increasingly recognizable neuro-clinical syndrome. Clinical and neurological manifestations of PRES include hypertension, headache, encephalopathy, seizures, and symmetrical white matter changes on brain MRI. Most common precipitants of PRES are acute medical illness, hypertensive crisis, eclampsia, immunosuppressive therapy, and chemotherapy. Bevacizumab is a monoclonal antibody that halts angiogenesis by inhibiting vascular endothelial growth factor. It has gained widespread popularity in oncology world especially for metastatic and recurrent cancers due to its inherent ability to stop angiogenesis; a vital step for tumor growth. Bevacizumab has also been implicated as the cause of PRES due to dysregulation of the blood-brain barrier. We are reporting a case of PRES induced by Bevacizumab in a patient of colorectal cancer. |
| first_indexed | 2024-04-11T02:25:32Z |
| format | Article |
| id | doaj.art-21ed61afdb0c4d0f91a37fc3d62db17e |
| institution | Directory Open Access Journal |
| issn | 2000-9666 |
| language | English |
| last_indexed | 2024-04-11T02:25:32Z |
| publishDate | 2018-05-01 |
| publisher | Greater Baltimore Medical Center |
| record_format | Article |
| series | Journal of Community Hospital Internal Medicine Perspectives |
| spelling | doaj.art-21ed61afdb0c4d0f91a37fc3d62db17e2023-01-02T22:39:14ZengGreater Baltimore Medical CenterJournal of Community Hospital Internal Medicine Perspectives2000-96662018-05-018313013310.1080/20009666.2018.14785631478563Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancerMohsin Hamid0Ali Ghani1Ida Micaily2Usman Sarwar3Bilal Lashari4Faizan Malik5Abington Hospital - Jefferson HealthAbington Hospital - Jefferson HealthAbington Hospital - Jefferson HealthAbington Hospital - Jefferson HealthAbington Hospital - Jefferson HealthUniversity of Maryland Medical CenterPosterior reversible encephalopathy syndrome (PRES) is an increasingly recognizable neuro-clinical syndrome. Clinical and neurological manifestations of PRES include hypertension, headache, encephalopathy, seizures, and symmetrical white matter changes on brain MRI. Most common precipitants of PRES are acute medical illness, hypertensive crisis, eclampsia, immunosuppressive therapy, and chemotherapy. Bevacizumab is a monoclonal antibody that halts angiogenesis by inhibiting vascular endothelial growth factor. It has gained widespread popularity in oncology world especially for metastatic and recurrent cancers due to its inherent ability to stop angiogenesis; a vital step for tumor growth. Bevacizumab has also been implicated as the cause of PRES due to dysregulation of the blood-brain barrier. We are reporting a case of PRES induced by Bevacizumab in a patient of colorectal cancer.http://dx.doi.org/10.1080/20009666.2018.1478563PRESRPLSBRESVEGFBevacizumabFOLFOXangiogenesis |
| spellingShingle | Mohsin Hamid Ali Ghani Ida Micaily Usman Sarwar Bilal Lashari Faizan Malik Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer Journal of Community Hospital Internal Medicine Perspectives PRES RPLS BRES VEGF Bevacizumab FOLFOX angiogenesis |
| title | Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer |
| title_full | Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer |
| title_fullStr | Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer |
| title_full_unstemmed | Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer |
| title_short | Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer |
| title_sort | posterior reversible encephalopathy syndrome pres after bevacizumab therapy for metastatic colorectal cancer |
| topic | PRES RPLS BRES VEGF Bevacizumab FOLFOX angiogenesis |
| url | http://dx.doi.org/10.1080/20009666.2018.1478563 |
| work_keys_str_mv | AT mohsinhamid posteriorreversibleencephalopathysyndromepresafterbevacizumabtherapyformetastaticcolorectalcancer AT alighani posteriorreversibleencephalopathysyndromepresafterbevacizumabtherapyformetastaticcolorectalcancer AT idamicaily posteriorreversibleencephalopathysyndromepresafterbevacizumabtherapyformetastaticcolorectalcancer AT usmansarwar posteriorreversibleencephalopathysyndromepresafterbevacizumabtherapyformetastaticcolorectalcancer AT bilallashari posteriorreversibleencephalopathysyndromepresafterbevacizumabtherapyformetastaticcolorectalcancer AT faizanmalik posteriorreversibleencephalopathysyndromepresafterbevacizumabtherapyformetastaticcolorectalcancer |